Claudin-9 (CLDN9) promotes gastric cancer progression by enhancing the glycolysis pathway and facilitating PD-L1 lactylation to suppress CD8+ T cell anti-tumor immunity
<i>CLDN9</i> expression is associated with GC development and progression. Mechanistically, <i>CLDN9</i> enhances the glycolysis pathway and facilitates PD-L1 lactylation through the PI3K/AKT/HIF1α signaling pathway, thereby suppressing anti-tumor immunity in CD8<sup>+</sup> T cells. <i>CLDN9</i> has the potential to serve as a novel prognostic marker and therapeutic target for GC.
Authors
- Wenhao Ouyang (ORCID: https://orcid.org/0000-0002-2913-8527)
- Haizhu Chen (ORCID: https://orcid.org/0000-0001-9810-1050)
- Herui Yao (ORCID: https://orcid.org/0000-0001-5520-6469)
- Zijia Lai
- Xingbin Hu
- Zhihong Liu (ORCID: https://orcid.org/0000-0002-4706-9174)
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen Memorial Hospital (CN)
- Nanfang Hospital (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Cancer Pathogenesis and Therapy
- Published
- 2024-09-26
- DOI
- https://doi.org/10.1016/j.cpt.2024.09.006
- Citations
- 9
- Primary Topic
- Cancer, Stress, Anesthesia, and Immune Response
- Type
- article
- Field-Weighted Citation Impact
- 3.47
Funders
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Science and Technology Planning Project of Guangdong Province
- Basic and Applied Basic Research Foundation of Guangdong Province